ClinicalTrialsFinder

HR Low-Positive/HER2-Negative Breast Neoplasms Clinical Trials in Beijing, Beijing Municipality

1 recruitingBeijing, Beijing Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700